Leukemia   

The patient presented with a numb chin, more to the right of his face; an MRI did report mandibular nerve opacity, which is non-specific per neuro-rad...

For example, if patients are unable to receive continuous infusion from home health agencies, or if prolonged hospitalization is cost-prohibitive.&nbs...

Have you changed your practice given BMT-CTN 1506/Morpho results? Would you utilize maintenance therapy in patients who achieve MRD- remission?

How does graft source, conditioning regimen, and indication for transplant affect your decision regarding G-CSF?

At the time of count recovery or do you continue it throughout induction and consolidation?

NGS results are pending

For a pediatric patient with B-ALL who needs elective surgery during maintenance, what are potential treatment options during the month recommended fo...

Do you re-challenge them? If so, what pre-medications do you give? Do you dose reduce the cytarabine? Or do you switch another regimen?

Presuming there are no matched unrelated donors.

What would you want community oncologists to know when following these patients? Are there any other special issues to follow especially in AYA?

For patients not on study, would you consider replacing missed doses of peg with a non-asparaginase based chemotherapy?

There are conflicting reports whether it contributes to renal insufficiency. If you do switch, what is your preferred TKI in this scenario?

What are the differences in approach to B lymphoid/myeloid and T lymphoid/myeloid MPAL?

What is the role of PD-1 inhibitors after CAR-T infusion, either as maintenance therapy or in the setting of relapsed disease? 

Are there other supportive care interventions that would otherwise be covered by hospice?

Especially with the current drug shortage of nelarabine.

Would you plan straight pediatric dosing using 2500 Units/m2 or a cap of 3750 Units as used in some adult ALL regimens due to excess liver/pancreas to...

Patient's leukemia has both T and Myeloid lineages 

Would you consider “bridging” therapy with something like an HMA?

Is it at neutrophil recovery, at documentation of CR on bone marrow biopsy, or is there a different point in time?

Does acute leukemia sub-type affect your decision? 

Do you limit it to post-pubertal patients? Do you offer it only if they will proceed with bone marrow transplantation after CAR-T?

What dose do you recommend?